, expression and intracellular localization were determined during development and in adult mouse tissues. Northern blot, Western blot, and histochemical studies show that the 220-kDa MLCK is widely expressed during development as well as in several adult smooth muscle and nonmuscle tissues. The 130-kDa MLCK is highly expressed in all adult tissues examined and is also detectable during embryonic development. Colocalization studies examining the distribution of 130-and 220-kDa mouse MLCKs revealed that the 130-kDa MLCK colocalizes with nonmuscle myosin IIA but not with myosin IIB or F-actin. In contrast, the 220-kDa MLCK did not colocalize with either nonmuscle myosin II isoform but instead colocalizes with thick interconnected bundles of F-actin. These results suggest that in vivo, the physiological functions of the 220-and 130-kDa MLCKs are likely to be regulated by their intracellular trafficking and distribution.
REGULATION OF MYOSIN motor activities is accomplished through the activation of several calcium-dependent and independent serine/threonine protein kinases that can phosphorylate myosin II regulatory light chain (RLC). The protein kinases that have been shown to phosphorylate RLC in vitro or in vivo include protein kinase C (PKC), protein kinase A (PKA), p21-activated kinase (PAK), death-associated protein kinase (DAPK), Rho-associated protein kinase (RhoK), and myosin light chain kinase (MLCK) (1, 3, 4, 11, 27, 37, 41) . The best characterized of these protein kinases is the conventional calcium-calmodulin (Ca 2ϩ /CaM)-dependent MLCK, which has been shown to associate with both actin and myosin in vitro and actin in vivo (5, 14, 26, 28, 29, 32, 35, 36, 40) . Cloning of MLCKs has shown that the sequences of the conventional MLCKs are highly conserved and that the masses of the proteins encoded by these cDNAs fall into two general sizes that vary slightly depending on the species. The larger or "nonmuscle" MLCKs, range in size between 206 and 220 kDa. The smaller or "smooth muscle" MLCKs range in size from 125 to 155 kDa (24) . The sequence of the larger MLCKs includes the entire coding region of the smaller MLCK, and the mass difference is the result of a large (ϳ995 residues) extension of the amino terminus (11) . Although not extensively characterized, the in vitro biochemical properties of the 206-to 220-kDa MLCKs appear to be indistinguishable from those of the smaller 125-to 155-kDa MLCKs (2, 26, 31) .
Despite the extensive overlap in sequence and the indistinguishable biochemical properties, recent reports have suggested that these highly related kinases may have distinct functional roles in cells (24) . For example, a recent report demonstrated that the large and small MLCKs are differentially distributed during cytokinesis and that they associate with actin via a repeated (DXRXXL) motif that spans the junction of the long and short forms (31) . In addition to the distinctions in intracellular trafficking, the expression pattern during development and in adult tissues of these kinases has been examined (6, 7, 30, 39) . Although these studies have provided some insight as to potential distinctions due to differences in expression between these highly related enzymes, it is not clear from these studies whether the larger-mass MLCK is a developmentally regulated form, an endothelium-specific form, or a form that is widely expressed during development and in adult tissues. In addition, the intracellular localization of either form of MLCK with respect to its substrate myosin II has not been determined, and a direct comparison between MLCK forms derived from the same species has been not made. To address these issues we used immunolocalization and in situ immunohistochemistry to characterize the ex-pression and distribution of the mouse 220-and 130-kDa MLCKs. These studies reveal that although the mouse 220-and 130-kDa MLCKs have identical biochemical properties in vitro, the intracellular localization and tissue expression pattern of these enzymes are distinct.
MATERIALS AND METHODS
Antibodies and cultured cells. To detect MLCKs, the following antibodies were used: K36, a monoclonal anti-chicken gizzard MLCK (Sigma), a polyclonal antibody against 130-to 150-kDa MLCK produced by immunization of rabbits with tissue-purified bovine tracheal MLCK (R57; Ref. 23), the previously described D119 Repeat antibody (8) , and an affinity-purified polyclonal antibody specific for residues 1-170 of the 220-kDa mouse MLCK (anti-220MLCK1-170). The affinity-purified polyclonal antibodies against nonmuscle myosin heavy chain (NMHC)-IIA and -IIB have been previously described (13) . The anti-Flag epitope (M2) antibody was obtained from Sigma.
Bovine aortic, lung, and brain microvessel endothelial cells were obtained from Dr. Peter DelVecchio (VEC Technologies, Rensselaer, NY). Human umbilical vein endothelial cells (HUVECs) were harvested from umbilical cords and maintained in culture as described previously (18) . Bovine pulmonary artery endothelial cells (BPAECs) were isolated from bovine pulmonary arteries and purified by Percoll gradient centrifugation based on a previous procedure (19) . The freshly isolated cells were either lysed without plating and then analyzed by Western blotting or plated and maintained in culture for several passages before lysis and Western blotting analysis. Primary cells and cell lines including rat embryo fibroblasts (REF-52), rat embryonic thoracic aorta smooth muscle cells (A10), and mouse cardiomyocytes (AT-2) were maintained in Dulbecco's minimal essential medium (DMEM) supplemented with 2 mM glutamine, 10% FCS, 50 U/ml penicillin, and 50 g/ml streptomycin.
Immunoprecipitation and activity measurements. Transfected cells expressing 220-kDa MLCK were washed with phosphate-buffered saline (PBS), and lysates were prepared in extraction buffer [25 mM Tris ⅐ HCl pH 6.8, 150 mM NaCl, 50 mM MgCl2, 1.0 mM EGTA, 1.0 mM EDTA, 1% NP-40, 0.5% Triton X-100, 0.2 mM phenylmethylsulfonyl fluoride, 100 g/ml benzamidine, 100 g/ml soybean trypsin inhibitor, and 10 g/ml each of N-tosyl-L-phenylalanine chloromethyl ketone (TPCK), N␣-p-tosyl-L-lysine chloromethyl ketone (TLCK), aprotinin, leupeptin, and pepstatin]. MLCK was immunoprecipitated, and assays to determine the specific activity of the recombinant murine 220-and 130-kDa MLCKs were performed as described previously (12) . Specific activity was estimated by using purified 150-kDa bovine tracheal MLCK as a standard. The MLCK proteins were detected with the anti-MLCK K36 monoclonal antibody, and densitometric scans were used to generate a standard curve and to compute the amount of the recombinant 220-kDa MLCK present in the extract. RLC phosphorylation assays were performed as described previously (18) .
Northern and Western blotting. Northern (21) and Western (13) blotting were performed as described previously. Equivalent amounts of total cellular protein or immunoprecipitates were fractionated by electrophoresis through an SDS-polyacrylamide gel and transferred to nitrocellulose. Immunoreactive proteins on Western blots were visualized with the Pierce West Pico or West Dura detection systems according to the manufacturer's directions. 32 P-phosphorylated RLCs were electrophoresed on 7.5-15% gradient SDS-polyacrylamide gels that were fixed in 50% methanol-10% acetic acid, dried at 70°C, and exposed to X-ray film. Labeled bands corresponding to the RLC were cut from the SDS-polyacrylamide gel, and tryptic peptide mapping and phosphoamino acid analysis were performed as described previously (17) .
Immunolocalization of MLCK in cells and embryos. Monolayers of microinjected cell cultures were washed with PBS, fixed in 3% formaldehyde in stabilization buffer for 1 h, and permeabilized with 0.1% Triton X-100 for 10 min at room temperature. For localization of F-actin, cells were stained with rhodamine phalloidin as described previously (18) . Cultures expressing Fl-130-MLCK were stained with 1.5 g/ml of mouse anti-Flag M2 antibody (Sigma) and then Alexa 488-conjugated goat anti-mouse IgG antibody (Molecular Probes). Where indicated, cells were incubated in 0.5 g/ml affinity rabbit NMHC-IIA or NMHC-IIB antibodies and then with Alexa 568-conjugated goat anti-rabbit IgG antibody. A Bio-Rad MRC 1024 confocal microscope was used to collect Z-series data images from both excitation channels simultaneously, and composite micrographs were constructed.
Immunohistochemistry of mouse adult tissues or embryos was as described previously (21) . Serial control sections were reacted with nonimmune serum (nonimmune IgG) or appropriate marker antibodies to facilitate identification of the tissue layers. The embryo figures each represent a compilation of ϳ170 individual images that were assembled by eye using overlap features in Photoshop. The images reacted with immune and preimmune sera were treated identically.
RESULTS
Cloning, expression, and detection of mouse 220-kDa MLCK. A cDNA library prepared from mouse AT-2 cardiomyocytes was screened with a probe corresponding to bp 421-2963 of the previously described mouse 130-kDa MLCK (bp 3170-5712 of 220-kDa MLCK) (21) . Thirty-eight positive lambda clones were obtained, purified, and sequenced to determine overlap and orientation of the fragments. Four overlapping clones were assembled to form a 6,270-bp cDNA. The largest open reading frame encoded a Ser/Thr protein kinase with a calculated molecular mass of 220 kDa. This cDNA differed from the mouse 130-kDa MLCK in that it has an additional 955 residues that extend the amino terminus (21) . An alignment with the previously cloned human endothelial MLCK revealed a high degree (ϳ85%) of identity between the mouse and human sequences and a lower identity (ϳ67%) between the mouse and chicken sequences. Please refer to the Supplementary Material 1 for this article (published online at the American Journal of Physiology-Cell Physiology web site) for the mouse 220-kDa MLCK, human endothelial MLCK, and chicken nonmuscle MLCK sequences. This alignment also revealed that the predicted open reading frame encoded by the mouse 220-kDa MLCK cDNA is extended at the amino terminus by an additional 44 residues compared with human and chicken sequences. The full-length cDNA for 220-kDa MLCK with a Flag epitope tag was expressed in cells and shown to comigrate with the endogenous 220-kDa MLCK, confirming that this cDNA encodes a full-length 220-kDa MLCK (Fig. 1A) .
To specifically detect the 220-kDa MLCK, a polyclonal antibody was produced in rabbits against purified recombinant protein representing residues 1-170 of the 220-kDa MLCK (220MLCK1-170). Western blotting was used to confirm that the antibody reacts only with recombinant and tissue-expressed 220-kDa MLCK (Fig. 1B) . In addition, no reactivity to the high level of 130-kDa MLCK present in mouse bladder and uterine smooth muscle tissues was detected (compare Fig. 1B with Fig. 2 ). Consistent with a previous study, the expression of 220-kDa MLCK in adult skeletal muscle is not detected (21) . Two commonly used anti-MLCK antibodies were characterized to determine Western blotting was used to characterize the specific reaction of an antibody to residues 1-107 of the 220-kDa MLCK with recombinant 220-kDa MLCK expressed in cells and the endogenous 220-kDa MLCK present in adult mouse bladder and uterine tissues. This antibody does not detect 130-kDa MLCK present in bladder and uterus. The lower-molecular-mass bands in some samples represent proteolytic degradation products. C: examination of the specificity of D119 and K36 antibodies for MLCK. Purified platelet myosin (NMHC-IIA) and COS cell extracts expressing either recombinant 220-or 130-kDa mouse MLCKs were analyzed by Western blotting to determine whether D119 repeat antibody and K36 antibodies specifically detect only MLCK. D119 cross-reacts with NMHC-IIA, and K36 is highly specific for MLCK. MM, molecular mass. D: mapping the epitope for monoclonal antibody K36. COS cells transiently expressing mutant 150-kDa rabbit MLCK (numbers indicate residues deleted) were examined to determine reactivity by Western blotting of the K36 monoclonal antibody. The smallest region analyzed that is undetectable by K36 is a deletion of residues 2-42. WT, wild type. E: alignment of residues corresponding to those between 2 and 42 of the 150-kDa rabbit MLCK and all cloned 210-to 220-kDa and 130-to 150-kDa MLCKs. Mo, mouse; CK, chicken; Hu, human; Rb, rabbit; Bov, bovine. their ability to detect MLCKs from tissues and cell types of different species. An antibody generated against a peptide representing a repeated sequence present in all mammalian 220-and 130-kDa MLCKs (D119 Repeat; Ref. 8) recognized both 220-and 130-kDa MLCKs as expected but was also found to crossreact with purified platelet myosin IIA (Fig. 1C) . To confirm this observation, REF-52 and BPAEC lysates were fractionated with a D119 antibody affinity column. The affinity-purified protein was identified as NMHC-IIA by direct amino acid sequencing (data not shown). Further support for this observation comes from an expression screen of a mouse AT-2 cDNA library in which D119 positive clones were sequenced and found to encode NMHC-IIA (data not shown). The epitope in MLCKs recognized by K36 monoclonal antibody was determined by using Western blotting of COS cell extracts in which deletion mutants of the 150-kDa rabbit MLCK that were transiently expressed. The results show that the K36 antibody binds between residues 2 and 42 of the rabbit 150-kDa MLCK (Fig.  1D) , and alignment of the sequences of all cloned MLCKs revealed a high degree of identity between residues 2 and 42 (Fig. 1E) . On the basis of this information, it is expected that the K36 antibody will detect both small-and large-molecular-mass MLCKs in human, chicken, mouse, or bovine tissues.
Biochemical characterization of mouse 220-kDa MLCK. To confirm that the cDNA encoding the mouse 220-kDa MLCK is catalytically active as well as to compare its in vitro biochemical properties with the previously described mouse 130-kDa MLCK, the 220-kDa MLCK was immunoprecipitated and used in an in vitro kinase assay ( Fig. 2A) . Immunopurified 220-kDa MLCK was incubated with RLCs in the presence and absence of Ca 2ϩ /CaM for 30 min at 30°C and analyzed by SDS-PAGE, and in this assay the 220-kDa MLCK phosphorylated both isolated RLCs and RLCs associated with purified platelet myosin. Consistent with the Ca 2ϩ /CaM dependence of the 130-kDa MLCK, the 220-kDa MLCK has minimal light chain phosphorylation activity in the presence of EGTA (Fig. 2B) .
One-dimensional tryptic peptide mapping and phosphoamino acid analysis were used to identify the site(s) in the RLC that are phosphorylated by 220-kDa MLCK. Figure 2C shows tryptic peptide maps of recombinant RLC phosphorylated in vitro by either PKC or 150-kDa rabbit MLCK. Tryptic peptide mapping of RLC phosphorylated by 220-kDa MLCK yielded two phosphopeptides that comigrate with the monophosphorylated S19 and diphosphorylated S19/18 standards. Phosphoamino acid analysis confirmed that both S and T residues are phosphorylated by 220-kDa MLCK, although at the low levels of 220-kDa MLCK used in the reaction, S19 predominates (Fig. 2D) . RLCs with mutations in key consensus recognition elements were utilized (3) as substrates for in vitro phosphorylation by 220-kDa MLCK confirmed the specificity of phosphorylation at S19 and T18 (Fig. 2E) . Mutation of T18 to A (T18A) resulted in a small effect on the level of phosphorylation, whereas mutation of S19 to A decreased phosphorylation by 12.5-fold. As expected, mutation of both S19 and T18 (TS18, 19AA) ablated RLC phosphorylation by 220-kDa MLCK and substitution of R16 with A (R16A) reduced the ability of 220-kDa MLCK to phosphorylate RLC by ϳ25-fold, consistent with the importance of the P-3 residue in the consensus recognition sequence.
Determination of the activity of the recombinant enzyme expressed in COS cells showed that the expressed protein was catalytically active and Ca 2ϩ /CaM dependent. The specific activity was estimated to be 21 pmol incorporated 32 ) and recombinant rabbit smooth muscle MLCKs (39.0 pmol ⅐ min Ϫ1 ⅐ ng Ϫ1 ) (10, 25) . Northern and Western blotting to determine expression profile of 220-and 130-kDa mouse MLCKs. Northern blots reacted with a cRNA probe corresponding to bp 180-367 (residues 1-63) of the mouse 220-kDa MLCK cDNA hybridized to a single mRNA of ϳ8.4 kb in various mouse embryos, adult tissues, and cell lines (Fig. 3A) . Among the group of adult tissues examined, the highest mRNA levels were detected in bladder, vas deferens, lung, liver, and kidney. With independently isolated samples of vas deferens mRNA, only an 8.4-kb mRNA is consistently found to react with the 220-kDa MLCK-specific probe, suggesting that the 4.0-and 2.4-kb mRNAs detected may be genomic DNA contamination of this sample. A second probe corresponding to bp 3170-5712 (residues 998-1865) of the mouse 220-kDa MLCK cDNA hybridized to mRNAs of 8.4 and 5.7 kb, which encode the 220-and 130-kDa MLCKs, respectively. The 5.7-kb mRNA is detectable in all tissues represented on this Northern blot, including both smooth muscle and nonmuscle tissues (Fig. 3A) . In addition, this probe detected the 2.4-kb mRNA corresponding to the smooth muscle-specific telokin protein (9, 22, 34) . Western blotting with the K36 monoclonal antibody detected a 220-kDa protein in many smooth muscle tissues including bladder, uterus, vas deferens, trachea, lung, and aorta (Fig. 3B) .
In situ immunohistochemical detection of 220-kDa MLCK in mouse embryos and adult tissues. To determine whether the 220-kDa MLCK is expressed in a tissue-specific manner, the pattern of expression of this MLCK was examined during mouse development and in adult mouse tissues. In situ immunohistochemical localization performed on mouse embryos at day 14.5 revealed that the expression of the 220-kDa MLCK is detectable throughout the entire embryo, suggesting that this form of MLCK is ubiquitously expressed (Fig.  4A) . However, in some areas of the developing brain and the lower gastrointestinal tract, as well as various blood vessels, there appeared to be a higher level of expression, a result consistent with the expression pattern of MLCK found during chicken embyrogenesis (7, 30) . In contrast, the expression of the 220-kDa MLCK was enriched in some but not all adult tissues with smooth muscle components (Fig. 4B) , although in these tissues, the expression of the 220-kDa MLCK was detectable in both the smooth muscle and nonmuscle layers (Fig. 4B) .
Expression of MLCK is downregulated in cultured primary cells. In culture, primary cells utilize new and unique types of contractile processes such as those required for adherence, migration, and proliferation, and thus it is reasonable to predict that if the 220-and 130-kDa MLCKs have distinct roles in regulating these functions their levels of expression may be altered when isolated primary cells are placed in culture. To examine this possibility, the expression level of both MLCK forms was examined by Western blotting with primary BPAECs. This study revealed that both 220-and 130-kDa MLCKs are highly expressed in purified primary BPAECs and that on culture the only detectable MLCK is the 220-kDa form (Fig. 5A) . To determine whether the purified primary BPAECs were contaminated with smooth muscle cells, the blot was probed with anti-smooth muscle ␣-actin monoclonal antibody (1A4). This blot shows that smooth muscle ␣-actin is not detectable in extracts of these Percoll gradient purified cells. Similarly, cell extracts prepared from cultures of primary bovine endothelial cells isolated from large (umbilical vein, aorta) and small (lung, brain) vessels revealed that only the 220-kDa MLCK is detectable after passage in culture (Fig. 5B) . Figure 5C shows that parallel results were obtained with primary cultures of smooth muscle cells. This Western blot shows that both 220-and 130-kDa MLCKs are detectable in extracts of bovine tracheal smooth muscle tissues and uncultured as well as cultured cells, with the 130-kDa MLCK being the predominant form. On culture, the 130-kDa MLCK exhibits a significant decrease in expression (10-fold) compared with the expression of the 220-kDa MLCK, which remained fairly constant between the initial (P0) and third (P3) pas- A: serial sections of mouse day 14.5 embryos were reacted with affinity-purified anti-220-kDa (1-170) antibody or preimmune control serum, followed by rhodamine-conjugated goat anti-rabbit IgG. The 220-kDa MLCK is detected in all tissues in the mouse day 14.5 embryo. The right and left ventricles of the heart (R vent, L vent) are indicated by arrows. The lines point to specific tissues that consistently had higher levels of expression of 220-kDa MLCK. B: localization of 220-kDa MLCK in adult tissues. Selected mouse adult tissues (vas deferens, bladder, aorta, and stomach) were fixed and reacted with antibodies to detect ␣-smooth muscle actin (fluorescence conjugated 1A4 antibody, Sm Actin), 220-kDa MLCK (1-170), or preimmune control serum followed by rhodamine-conjugated second antibody. Center panels, localization of 220-kDa MLCK with respect to the smooth muscle layers of the tissues detected in left panels with the ␣-smooth muscle actin antibody. (8, 10) blotting, were injected with MLCK expression plasmid constructs and used for immunolocalization studies. Expressed GFP-220-kDa MLCK (Fig. 6, A-C) in REF-52 cells colocalized with thick actin bundles, and the expressed 130-kDa MLCK exhibited a diffuse localization throughout the cytoplasm with a few fine filamentous structures that do not appear to strongly colocalize with F-actin filaments (Fig. 6, D-F) . Similar results were obtained using BPAECs transiently expressing these MLCKs (data not shown).
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To determine whether the MLCKs colocalize with their substrate, nonmuscle myosin II, the distribution of NMHC-IIA and -IIB was examined in BPAECs expressing either Fl-130-kDa (Fig. 7) or GFP-220-kDa (Fig. 8) MLCK. In BPAECs, the filamentous structures corresponding to NMHC-IIA (Figs. 7B and 8B) are distinct from those of NMHC-IIB (Figs. 7E and 8E) , with the NMHC-IIA consistently having thicker filaments and a more apparent periodic distribution. The distribution of the 130-kDa MLCK is primarily concentrated at the cell periphery and in the perinuclear region, although a small amount of the expressed protein does exhibit a filamentous pattern (Fig. 8, A and  D) that overlaps with NMHC-IIA (Fig. 8, B and C) , although this overlap may be coincidental because some of the 130-kDa MLCK has a diffuse cytoplasmic distribution. However, it is clear that the intracellular distribution of the 130-kDa MLCK does not overlap with NMHC-IIB filaments, which appear in a different plane in the cell (Fig. 8F) . Unexpectedly, the 220-kDa MLCK does not colocalize with either NMHC-IIA or -IIB (Fig. 8, A-F) .
DISCUSSION
A comparison of the deduced amino acid sequence of the mouse 220-kDa MLCK to the 214-kDa human and 210-kDa chicken MLCKs revealed a high degree of identity. In particular, there was a higher degree of sequence identity (84%) between the mouse and human cDNAs than between either the mouse and chicken (67%) or human and chicken (65%) sequences. This high degree of sequence conservation has suggested that regions amino-and carboxyl-terminal of the kinase domain and regulatory regions may have important and specific functions. Proposed functions for these regions include protein-protein interactions such as those required for intracellular localization (14, 31, 36) and sites for regulation of signal-transducing activities (2) . Our studies extensively compare for the first time the properties of the 130-and 220-kDa forms of the mouse MLCKs both in vitro and in vivo.
Our in vitro biochemical studies have shown that the 220-kDa MLCK, like the 130-kDa MLCK, specifically phosphorylates only S19 and T18 in the myosin II RLC and that this activity is dependent on Ca 2ϩ /CaM. Northern and Western blotting and in situ immunohistochemistry demonstrated that the expression of 220-kDa MLCK is not restricted to a specific cell or tissue type in embryos. Similarly, in adult tissues the 220-kDa MLCK is expressed in both the nonmuscle as well as smooth muscle components of many mouse tissues, although it was not detectable in heart, skeletal muscle, testes, or tissues derived from the upper gastrointestinal tract. However, it is possible that the level of expression of the mouse 220-kDa MLCK in these tissues is below the sensitivity of detection by the techniques used in these studies. We noted some discordance between our Northern and Western blotting results, which show that in undifferentiated embryonic stem cells or day 10 (E10) embryos an 8.4-kb mRNA is present but no 220-kDa MLCK is detected by Western blotting. There also appears to be a lower level of expression of the 220-kDa MLCK in adult liver, lung, and kidney and E10 whole embryos than would be predicted from the mRNA levels. One possibility to account for this is that in these tissues the mRNAs and proteins are regulated either by posttranscriptional or posttranslational mechanisms. In contrast to the 220-kDa MLCK, expression of the 130-kDa MLCK is detected in day 10, 15, and 19 embryos as well as all adult tissues (8, 10) with only embryonic stem and AT2 cells having undetectable levels of 130-kDa MLCK. Together these results show that the 220-and the 130-kDa MLCKs, which have been descriptively referred to as nonmuscle and smooth muscle MLCKs, respectively, are not tissue-specific proteins, although higher relative levels of expression of both of these MLCKs are detected in smooth muscle tissues. This finding, together with our identification of at least one additional lower (ϳ100 kDa)-molecular-mass MLCK derived from the MYLK gene (B. P. Herring and P. J. Gallagher, unpublished observation), leads us to suggest the use of molecular mass, rather than tissue-specific (nonmuscle/smooth muscle) or long/short nomenclature, to refer to MLCKs.
The coincidental expression of the 130-and 220-kDa MLCKs during development and in adult tissues raises the question as whether or not these closely related protein kinases have distinctive functional or regulatory roles to account for their redundant expression. This prompted a closer examination of the intracellular distribution of these kinases with respect to actin and myosin filaments in cells. The overlap in protein structure between the 220-and 130-kDa MLCKs excludes the possibility of an antibody that reacts exclusively with the 130-kDa MLCK, and thus we utilized epitopetagged versions of these kinases for these studies. These immunolocalization studies revealed that the intracellular distribution of the overexpressed recombinant 130-kDa MLCK does not overlap with F-actin filaments or with NMHC-IIB but may partially overlap with NMHC-IIA filaments that extend beyond the perinuclear region and flow toward the leading edges of the cell. In contrast, the immunofluorescence pattern of the 220-kDa MLCK showed a high degree of coincidence with thick actin cables but did not overlap with either of the two nonmuscle myosin forms (NMHC-IIA and NMHC-IIB) found in endothelial cells (BPAECs; suggestion that one function of the 220-kDa MLCK is to bind to and assemble F-actin filaments into thick bundles (20, 26, 31) . One explanation for why this property is specific to the 220-kDa MLCK is that the larger number of DXRXXL actin binding motifs in the 220-kDa MLCK potentially increases its binding to actin and contributes to a bundling activity as suggested previously (31) . Because REF cells used in these studies lack endogenous expression of both the 220-and 130-kDa MLCKs, the absence of colocalization of the recombinant 130-kDa MLCK with actin or the partial localization with NMHC-IIA filaments in these cells cannot be the result of a competition by the endogenous MLCKs for binding sites on these filaments, although it is possible that these cells may lack a binding site or localizing protein specific for the 130-but not the 220-kDa MLCK. Together these results support the proposal that the 220-and 130-kDa MLCKs have unique intracellular distributions, which may result in distinct regulatory functions. The finding that isolated primary endothelial and smooth muscle cells extensively downregulate the expression level of the 130-kDa MLCK when placed in culture suggests that the contractile functions regulated by the 130-kDa MLCK may be less essential in isolated, adherent, proliferating cells than those regulated by the 220-kDa MLCK and is supportive of unique functional roles for these kinases.
The finding that a previously described anti-MLCK antibody (D119) also cross-reacted with purified NMHC-IIA in addition to both the smaller and larger MLCK forms calls into question studies that have used this antibody for Western blotting to identify a putative novel embryonic MLCK (8) . In addition, these results also suggest that the D119 antibody should be used with caution to detect the large 220-kDa MLCK, which has a molecular mass similar to that of nonmuscle myosin IIA (15, 38, 39) . The basis for this cross-reaction appears to result from an overlap in the peptide sequence (KPVGNAKPAETL) used to generate this antibody and a sequence present at the extreme carboxyl terminus of NMHC-IIA (KPAE residues 1948-1951) (33) .
In summary, a full-length mouse 220-kDa MLCK has been cloned, expressed in cells, and found to have in vitro biochemical properties that are indistinguishable from those of the 130-to 150-kDa MLCKs. Like the 130-kDa MLCK, the 220-kDa MLCK does not appear to be an embryonic form and is not expressed in a tissue-specific manner, although its expression is undetectable in several adult tissues including cardiac, skeletal, and gastrointestinal tract. This study also revealed that the intracellular distributions of the 210-to 220-kDa and 130-to 150-kDa MLCKs are distinct, supporting the proposal that these highly related kinases may have specific and unique functions that regulate contractile processes in cells and tissues.
